Ascletis has announced that its Ganovo phase III clinical study won the top clinical research award at the 15th National Congress of Chinese Society of the Infectious Disease. Professor Wei Lai, the Director of the Institute of Hepatology of Peking University and principal investigator of Ganovo's clinical trial, was pleased to accept this award based on a unanimous vote by a professional reviewing committee of top national experts. The winning paper gained the highest merit out of 577 conference papers submitted this year. The Ganovo regimen demonstrated excellent results with a cure rate of 97 percent (SVR12) in genotype 1 non-cirrhotic patients within a 12-week treatment duration.
Professor Wei Lai said, "This award showcased the outstanding recognition to Ganovo from the China Medical Association (CMA) and KOL's endorsement to China-driven self-innovation encouraged by the fast growth of the China bio-tech industry in recent years. As the first Direct-acting Anti-viral Agent (DAA) developed and launched successfully by a domestic company in China, Ganovo has shown excellent efficacy, safety and tolerability. I sincerely hope Ganovo will make a larger impact and significant contribution to the elimination of HCV disease in China."
The National Congress of Chinese Society of the Infectious Disease is the largest and most influential academic conference in China, attracting more than 2,000 experts and doctors in 2018. The award further reinforces the medical community's confidence in Ganovo's excellent efficacy, safety and tolerability, and Ascletis’ strong commitment to high quality drugs, and service to Chinese patients.
The launching conference for Ganovo (Danoprevir sodium tablets) was held at the China National Convention Center, Beijing. Having an indigenous product has helped to break the monopoly in China of hepatitis C small molecular antiviral drugs by the international pharmaceutical giants. Ascletis Pharmaceutical Co., Ltd. is dedicated to the development and commercialization of innovative drugs against hepatitis C virus (HCV), AIDS (HIV) and hepatitis B virus (HBV). Ascletis currently has five programs of antiviral drug discovery and development.
For more clinical development news, visit our Drug Discovery & Development community